{
    "organizations": [],
    "uuid": "175f8082f150abfdc71909af995ca64dc8465bbd",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-onconova-presents-data-on-dual-inh/brief-onconova-presents-data-on-dual-inhibitor-of-cdk4-6-ark5-at-american-association-for-cancer-research-2018-annual-meeting-idUSFWN1RW0LS",
    "ord_in_thread": 0,
    "title": "BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 19 (Reuters) - Onconova Therapeutics Inc:\n* ONCONOVA PRESENTS DATA ON DUAL INHIBITOR OF CDK4/6 + ARK5 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL MEETING\n* ONCONOVA THERAPEUTICS INC - RECEIVES PRODUCTIVE PRE-IND GUIDANCE FROM FDA REGARDING FIRST-IN-CLASS COMPOUND ON 123300\n* ONCONOVA THERAPEUTICS INC - DEVELOPMENT PROGRAM IS IN COLLABORATION WITH HANX BIOPHARMACEUTICALS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-19T20:47:00.000+03:00",
    "crawled": "2018-04-20T11:25:43.005+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "onconova",
        "therapeutic",
        "inc",
        "onconova",
        "present",
        "data",
        "dual",
        "inhibitor",
        "ark5",
        "american",
        "association",
        "cancer",
        "research",
        "annual",
        "meeting",
        "onconova",
        "therapeutic",
        "inc",
        "receives",
        "productive",
        "guidance",
        "fda",
        "regarding",
        "compound",
        "onconova",
        "therapeutic",
        "inc",
        "development",
        "program",
        "collaboration",
        "hanx",
        "biopharmaceuticals",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}